REFERENCES
1. Society AC. Cancer Treatment & Survivorship Facts & Figures 2016-2017. 2017.
2. Haggar FA, Pereira G, Preen D, Holman CD, Einarsdottir K. Adverse obstetric and perinatal outcomes following treatment of adolescent and young adult cancer: a population-based cohort study. PLoS One.2014;9(12):e113292.
3. van der Kooi ALF, Brewster DH, Wood R, et al. Perinatal risks in female cancer survivors: A population-based analysis. PLoS One.2018;13(8):e0202805.
4. Anderson C, Engel SM, Mersereau JE, et al. Birth Outcomes Among Adolescent and Young Adult Cancer Survivors. JAMA Oncol.2017;3(8):1078-1084.
5. Gorman JR, Bailey S, Pierce JP, Su HI. How do you feel about fertility and parenthood? The voices of young female cancer survivors.J Cancer Surviv. 2012;6(2):200-209.
6. Gorman JR, Malcarne V, Pierce JP, Su HI. A multidimensional scale to measure the reproductive concerns of young adult cancer survivors.Journal of Cancer Survivorship. 2013.
7. Gorman JR, Su HI, Pierce JP, Roberts SC, Dominick SA, Malcarne VL. A multidimensional scale to measure the reproductive concerns of young adult female cancer survivors. J Cancer Surviv.2014;8(2):218-228.
8. van der Kooi ALF, Kelsey TW, van den Heuvel-Eibrink MM, Laven JSE, Wallace WHB, Anderson RA. Perinatal complications in female survivors of cancer: a systematic review and meta-analysis. Eur J Cancer.2019;111:126-137.
9. Kao WH, Kuo CF, Chiou MJ, et al. Adverse birth outcomes in adolescent and young adult female cancer survivors: a nationwide population-based study. Br J Cancer. 2020;122(6):918-924.
10. Goldenberg RL, Culhane JF, Iams JD, Romero R. Epidemiology and causes of preterm birth. Lancet. 2008;371(9606):75-84.
11. Farland LV, Stern JE, Hwang SS, et al. Early-life cancer, infertility, and risk of adverse pregnancy outcomes: a registry linkage study in Massachusetts. Cancer Causes Control.2021;32(2):169-180.
12. American College of O, Gynecologists, the Society for Maternal-Fetal M, Kilpatrick SK, Ecker JL. Severe maternal morbidity: screening and review. Am J Obstet Gynecol. 2016;215(3):B17-22.
13. Rivara FP, Fihn SD. Severe Maternal Morbidity and Mortality: JAMA Network Open Call for Papers. JAMA Netw Open. 2020;3(1):e200045.
14. Chao C, Xu L, Bhatia S, et al. Cardiovascular Disease Risk Profiles in Survivors of Adolescent and Young Adult (AYA) Cancer: The Kaiser Permanente AYA Cancer Survivors Study. J Clin Oncol.2016;34(14):1626-1633.
15. Ethics Committee of the American Society for Reproductive Medicine. Electronic address Aao. Fertility preservation and reproduction in patients facing gonadotoxic therapies: an Ethics Committee opinion.Fertil Steril. 2018;110(3):380-386.
16. Technology SfAR. sart.org. Accessed.
17. Dunietz GL, Holzman C, McKane P, et al. Assisted reproductive technology and the risk of preterm birth among primiparas. Fertil Steril. 2015;103(4):974-979 e971.
18. Belanoff C, Declercq ER, Diop H, et al. Severe Maternal Morbidity and the Use of Assisted Reproductive Technology in Massachusetts.Obstet Gynecol. 2016;127(3):527-534.
19. Wallace PJ, Shah ND, Dennen T, Bleicher PA, Crown WH. Optum Labs: building a novel node in the learning health care system. Health Aff (Millwood). 2014;33(7):1187-1194.
20. Matcho A, Ryan P, Fife D, Gifkins D, Knoll C, Friedman A. Inferring pregnancy episodes and outcomes within a network of observational databases. PLoS One. 2018;13(2):e0192033.
21. Hornbrook MC, Whitlock EP, Berg CJ, et al. Development of an algorithm to identify pregnancy episodes in an integrated health care delivery system. Health Serv Res. 2007;42(2):908-927.
22. Bandoli G, Chambers CD, Wells A, Palmsten K. Prenatal Antidepressant Use and Risk of Adverse Neonatal Outcomes. Pediatrics.2020;146(1).
23. Margulis AV, Setoguchi S, Mittleman MA, Glynn RJ, Dormuth CR, Hernandez-Diaz S. Algorithms to estimate the beginning of pregnancy in administrative databases. Pharmacoepidemiol Drug Saf.2013;22(1):16-24.
24. Li Q, Andrade SE, Cooper WO, et al. Validation of an algorithm to estimate gestational age in electronic health plan databases.Pharmacoepidemiol Drug Saf. 2013;22(5):524-532.
25. Nina Veeravalli ST, Gretchen Bandoli. Family Ties: Linking Mothers and Newborns in a Large, De-Identified Claims Database. AcademyHealth Annual Research Meeting; 2019; Washington, D.C.
26. Institute NC. Surveillance, Epidemiology, and End Results (SEER). In.
27. Abraha I, Montedori A, Serraino D, et al. Accuracy of administrative databases in detecting primary breast cancer diagnoses: a systematic review. BMJ Open. 2018;8(7):e019264.
28. Lemos EV, Zhang D, Van Voorhis BJ, Hu XH. Healthcare expenses associated with multiple vs singleton pregnancies in the United States.Am J Obstet Gynecol. 2013;209(6):586 e581-586 e511.
29. Martin AS, Monsour M, Kissin DM, Jamieson DJ, Callaghan WM, Boulet SL. Trends in Severe Maternal Morbidity After Assisted Reproductive Technology in the United States, 2008-2012. Obstet Gynecol.2016;127(1):59-66.
30. Bateman BT, Mhyre JM, Ehrenfeld J, et al. The risk and outcomes of epidural hematomas after perioperative and obstetric epidural catheterization: a report from the Multicenter Perioperative Outcomes Group Research Consortium. Anesth Analg. 2013;116(6):1380-1385.
31. Bateman BT, Mhyre JM, Hernandez-Diaz S, et al. Development of a comorbidity index for use in obstetric patients. Obstet Gynecol.2013;122(5):957-965.
32. Division of Reproductive Health NCfCDPaHP. How Does CDC Identify Severe Maternal Morbidity? : CDC;2019.
33. Luke B, Brown MB. Contemporary risks of maternal morbidity and adverse outcomes with increasing maternal age and plurality.Fertil Steril. 2007;88(2):283-293.
34. VanderWeele TJ. A unification of mediation and interaction: a 4-way decomposition. Epidemiology. 2014;25(5):749-761.
35. Valente MJ, Rijnhart JJM, Smyth HL, Muniz FB, MacKinnon DP. Causal Mediation Programs in R, Mplus, SAS, SPSS, and Stata. Struct Equ Modeling. 2020;27(6):975-984.
36. Tang M, Webber K. Fertility and pregnancy in cancer survivors.Obstet Med. 2018;11(3):110-115.
37. D’Alton ME, Bonanno CA, Berkowitz RL, et al. Putting the ”M” back in maternal-fetal medicine. Am J Obstet Gynecol.2013;208(6):442-448.
38. Bombard JM, Robbins CL, Dietz PM, Valderrama AL. Preconception care: the perfect opportunity for health care providers to advise lifestyle changes for hypertensive women. Am J Health Promot. 2013;27(3 Suppl):S43-49.
39. Wiles KS, Bramham K, Vais A, et al. Pre-pregnancy counselling for women with chronic kidney disease: a retrospective analysis of nine years’ experience. BMC Nephrol. 2015;16:28.
40. Rolnik DL, Wright D, Poon LC, et al. Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia. N Engl J Med.2017;377(7):613-622.
41. Alina Zgardau PCN, Sumit Gupta, Joel G. Ray, Nancy N. Baxter, Chenthila Nagamuthu, Cindy Lau, Alison Park. Obstetrical and perinatal complications in survivors of childhood, adolescent, and young adult cancer: A population-based study. Journal of Clinical Oncology.2020;38:10529.
42. Fingar KR, Hambrick MM, Heslin KC, Moore JE. Trends and Disparities in Delivery Hospitalizations Involving Severe Maternal Morbidity, 2006-2015: Statistical Brief #243. In: Healthcare Cost and Utilization Project (HCUP) Statistical Briefs. Rockville (MD)2006.
43. Practice Committee of the American Society for Reproductive Medicine. Electronic address Aao, Practice Committee of the Society for Assisted Reproductive T. Guidance on the limits to the number of embryos to transfer: a committee opinion. Fertil Steril.2017;107(4):901-903.
44. Norwitz ER, Edusa V, Park JS. Maternal physiology and complications of multiple pregnancy. Semin Perinatol. 2005;29(5):338-348.
45. Metcalfe A, Lix LM, Johnson JA, et al. Validation of an obstetric comorbidity index in an external population. BJOG.2015;122(13):1748-1755.
46. Virnig BA, McBean M. Administrative data for public health surveillance and planning. Annu Rev Public Health.2001;22:213-230.
47. Clapp MA, James KE, Kaimal AJ, Sommers BD, Daw JR. Association of Medicaid Expansion With Coverage and Access to Care for Pregnant Women.Obstet Gynecol. 2019;134(5):1066-1074.
48. Lund JL, Sturmer T, Harlan LC, et al. Identifying specific chemotherapeutic agents in Medicare data: a validation study. Med Care. 2013;51(5):e27-34.
49. Lamont EB, Lan L. Sensitivity of Medicare claims data for measuring use of standard multiagent chemotherapy regimens. Med Care.2014;52(3):e15-20.
50. Zhou B, Kwan B, Desai MJ, et al. Long-term antimullerian hormone patterns differ by cancer treatment exposures in young breast cancer survivors. Fertil Steril. 2022.